Keros Therapeutics (KROS) Other Gross PP&E Adjustments (2019 - 2025)
Keros Therapeutics (KROS) has disclosed Other Gross PP&E Adjustments for 7 consecutive years, with -$15.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 19.6% year-over-year to -$15.8 million, compared with a TTM value of -$15.8 million through Dec 2025, up 19.6%, and an annual FY2025 reading of -$15.8 million, up 19.6% over the prior year.
- Other Gross PP&E Adjustments was -$15.8 million for Q4 2025 at Keros Therapeutics, up from -$17.5 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $1.1 million in Q4 2021 and bottomed at -$20.3 million in Q4 2023.
- Average Other Gross PP&E Adjustments over 5 years is -$10.4 million, with a median of -$14.8 million recorded in 2024.
- The sharpest move saw Other Gross PP&E Adjustments skyrocketed 96.47% in 2021, then tumbled 3405.37% in 2023.
- Year by year, Other Gross PP&E Adjustments stood at $1.1 million in 2021, then tumbled by 1196.59% to -$12.2 million in 2022, then tumbled by 65.96% to -$20.3 million in 2023, then rose by 3.21% to -$19.6 million in 2024, then rose by 19.6% to -$15.8 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for KROS at -$15.8 million in Q4 2025, -$17.5 million in Q3 2025, and -$18.1 million in Q2 2025.